Here’s what you should know:
1. Researchers based the compound off Solanum nigrum Linn. In animal models, the compound was 10 times more cytotoxic to HepG2 liver cancer cells than market alternatives.
2. Q BIoMed and The Oklahoma Medical Research Foundation worked to advance the treatment’s development.
3. The compound causes no noticeable side effects in animals models.
4. Q BioMed CEO Denis Corin said in a release, “Our ultimate goal is to use [the compound] as a chemotherapeutic against liver cancer, which has very few therapeutic options.”
More articles on gastroenterology:
GI leader to know: Dr. David Schwartz of Vermont Gastroenterology
Exact Sciences pockets $238M from secondary stock sale — 3 key notes
Clarivate Analytics ranks AGA’s flagship magazine highest of 79 journals
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
